Holen Sie sich die Stockscreener-App
73.09
1.18%
-0.87
Schlusskurs vom Vortag:
$73.96
Offen:
$73.93
24-Stunden-Volumen:
1.80M
Relative Volume:
0.97
Marktkapitalisierung:
$12.08B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-34.77
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
-2.00%
1M Leistung:
-1.54%
6M Leistung:
-6.74%
1J Leistung:
+107.41%
1-Tages-Spanne:
$72.30
$73.95
1-Wochen-Bereich:
$72.30
$75.85
52-Wochen-Spanne:
$34.84
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
73.09 | 12.22B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Liquidity Mapping Around (IONS) Price Events - Stock Traders Daily
IONS Reiterated by TD Cowen -- Price Target Maintained at $108 - GuruFocus
Ionis Pharmaceuticals Stock (US46120E6023): Analyst updates keep biotech in focus - AD HOC NEWS
Insider plans 8,000-share sale at IONS (NASDAQ: IONS) on 06/15/2026 - Stock Titan
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
IONS (IONS) files Form 144 listing option-exercise shares on Nasdaq - Stock Titan
Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia - TipRanks
Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS) - Stock Titan
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy - MSN
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Sells 21,021 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Adds Veteran Leader to Board - The Globe and Mail
Ionis Pharmaceuticals, Inc. (IONS) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IONS) 2026-06-08 - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ: IONS) director Peter Reikes files baseline Form 3 - Stock Titan
Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com - Investing.com South Africa
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Lelezard
Ionis Pharmaceuticals adds Ludwig Hantson to board - Investing.com
Ionis’ ASO for ultra-rare neurological disorder awaits FDA’s decision - BioXconomy
CenterBook Partners LP Acquires Shares of 153,949 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital World Investors Has $1.42 Billion Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis updates time for fourth quarter and full year 2025 financial results webcast - Business Wire
Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Ionis Pharmaceuticals (IONS) Edges Lower Amidst Sector Headwinds; Key Support Levels in FocusVanna Flow - newsline.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals, Inc. Balance Sheet – XETR:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI - TradingView
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates - Yahoo Finance
TD Asset Management Inc Trims Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires 19,554 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak - TradingView
Why (IONS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG T - GuruFocus
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - standard-journal.com
Ionis Pharmaceuticals director sells $605,360 in stock - Investing.com UK
Ionis Pharmaceuticals director sells $605,360 in stock By Investing.com - Investing.com Canada
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing - marketscreener.com
Geode Capital Management LLC Boosts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
IONS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $125 - GuruFocus
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):